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Abstract
Background: Studies on time to diagnosis are an increasing field of clinical research that may help to plan
corrective actions and identify inequities in access to healthcare. Specific features of time to diagnosis studies, such
as how participants were selected and how time to diagnosis was defined and measured, are poorly reported. The
present study aims to derive a reporting guideline for studies on time to diagnosis.
Methods: Each item of a list previously used to evaluate the completeness of reporting of studies on time to
diagnosis was independently evaluated by a core panel of international experts (n = 11) for relevance and
readability before an open electronic discussion allowed consensus to be reached on a refined list. The list was
then submitted with an explanatory document to first, last and/or corresponding authors (n = 98) of published
systematic reviews on time to diagnosis (n = 45) for relevance and readability, and finally approved by the core
expert panel.
Results: The refined reporting guideline consists of a 19-item checklist: six items are about the process of
participant selection (with a suggested flowchart), six about the definition and measurement of time to diagnosis,
and three about optional analyses of associations between time to diagnosis and participant characteristics and
health outcomes. Of 24 responding authors of systematic reviews, more than 21 (≥88 %) rated the items as
relevant, and more than 17 (≥70 %) as readable; 19 of 22 (86 %) authors stated that they would potentially use the
reporting guideline in the future.
Conclusions: We propose a reporting guideline (REST) that could help authors, reviewers, and editors of time to
diagnosis study reports to improve the completeness and the accuracy of their reporting.
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Background
Time to diagnosis (TTD) is the interval from first alert
symptoms to the diagnosis of a disease in a patient [1–3].
Studies on TTD may aim at (1) measuring the length of
TTD and its evolution over time, (2) identifying the
determinants of long TTD (i.e., relationship between TTD
and patient or healthcare system characteristics), and/or
(3) evaluating relationships between long versus short
TTD and patient outcomes [1, 4]. The number of pub-
lished studies on TTD is rapidly increasing [4]. TTD is
also of increasing concern among patient advocacy
groups, and some, such as the International Confederation
of Childhood Cancer Parent Organizations, have estab-
lished a reduction in TTD as a priority [5]. There are
strong and common beliefs that longer TTD is associated
with worse health outcomes, as revealed by various sys-
tematic reviews of the literature [1–3]. Furthermore, in
* Correspondence: elise.launay@chu-nantes.fr
1Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé),
Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris
Descartes University, INSERM U1153, Maternité de Port-Royal, 53 Avenue de
l’Observatoire, 75014 Paris, France
2CHU de Nantes, Hôpital Mère-Enfant, Services de Pédiatrie Générale et
d’Urgences Pédiatriques, Nantes, France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Launay et al. BMC Medicine  (2016) 14:146 
DOI 10.1186/s12916-016-0690-7
PubMed, the definition of the Medical Subject Heading
“early diagnosis” includes the following statement:
‘Generally, early diagnosis improves prognosis and treat-
ment outcome’ [6]. However, many primary studies and
systematic reviews do not report worse patient out-
comes as a consequence of longer versus shorter TTD,
or have found inverse relationships between longer
TTD and better patient outcomes [1, 2]. These para-
doxical associations are due to incomplete adjustment
and residual confounding, as observed in studies of
TTD of pediatric brain and bone tumors [2, 7, 8]. An-
other issue associated with “early diagnosis” is related
to the risk of over-diagnosis and over-treatment [9].
Studies on TTD are most commonly based on series
of diagnosed cases and therefore have specific design
features exposing them to risk of bias and threats to the
generalizability of their findings [1]. For example, bias
may be introduced by how participants were selected,
how TTD was defined and measured, and how the asso-
ciation with participant characteristics and health out-
comes was assessed [1, 2, 4]. In a systematic review
evaluating the quality of reporting of 50 studies on TTD,
we found that these critical methodological aspects were
rarely reported. Hence, critical appraisal of these studies
by authors of systematic reviews was found frequently
inadequate [4].
In a previous work, we showed that the reporting of pri-
mary studies on TTD was poor, notably for their specific
design features. We therefore hypothesized that available
reporting guidelines (e.g., STROBE [10], STARD [11], and
Aarhus statement [12]) could be insufficient for accurate
and complete reporting of studies on TTD [1, 4]. A first
checklist was previously developed by some of us to evalu-
ate the completeness of reporting of studies on TTD in
the field of pediatrics [1]. The aim of the present study
was to derive a Reporting guideline for studies on TTD,
using this previous checklist and the expertise of two inde-
pendent international panels [13].
Methods
General methodology
We followed the EQUATOR network recommendations
for developing reporting guidelines [13]. We used a three-
step process: a discussion and refinement step with a core
panel of experts (referred below as the “scientific commit-
tee”), a rating step in which we invited authors of all sys-
tematic reviews on TTD, and a final discussion and
approval by the scientific committee (Fig. 1). We declared
the development of the present reporting guideline to the
EQUATOR network; a summary of our protocol was pub-
lished online [14].
First version of the checklist
A preliminary checklist of 25 items was submitted to the
scientific committee. This checklist included 23 (of 35)
items generated in previous work in which we had eval-
uated the quality of reporting of studies on TTD in the
field of pediatrics (Additional file 1) [1]. These 23 items
Fig. 1 Flow of the refinement, rating, and final approval process of the checklist for the reporting of studies on time to diagnosis
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had been considered potentially related to risk of bias
and threats to generalizability [1]. The 12 other items
were generic (e.g., aim of the study and inclusion cri-
teria) common with other related reporting guidelines
(e.g., STROBE, STARD); they were not initially submit-
ted to the scientific committee but were reintegrated
during the discussion process (Fig. 1). Two items from
the Aarhus statement concerning TTD definition and
measurement were added [12].
Discussion and refinement step
We identified 16 potential members for the scientific
committee, comprising clinical research methodologists,
clinical epidemiologists, clinicians, specialists in the field
of TTD studies, and medical editors. We invited them to
participate in an online survey by rating the relevance
and readability of each item. We asked them to answer
“yes” or “no” to the two following questions: “Is this item
relevant?” and “Is this item readable?” Experts from the
scientific committee were also invited to provide com-
ments and to suggest additional items. After the first
round of rating, we collated and anonymized all answers
and comments, and sent them back to members of the
scientific committee, together with a revised version of
the checklist. Members of the scientific committee were
then invited to provide feedback on the revised check-
list and to propose modifications through an online
general discussion. Revisions were made until we ob-
tained agreement from all members of the scientific
committee. The revised checklist was then used in the
second broad rating step.
Broad rating step
We invited the first author, last author and correspond-
ing (if different) author of each systematic review on
TTD identified in a previous methodological review [4]
to participate in an online survey in SurveyMonkey®.
Authors from this broad panel were asked to rate the
relevance and the readability of each item using the same
questions as in the core refinement step. We added the
possibility to answer “I don’t know” to the question on
relevance. Experts could also leave comments on each
item or the checklist and were asked if they would use this
reporting guideline to report a study on TTD in the
future. To facilitate understanding of items specific to
studies on TTD, we provided a document with explana-
tions and examples alongside the survey. Non-responders
were sent two reminders. None of the 11 experts in the
scientific committee participated in the broad rating step.
Finalization of the checklist and the explanatory document
Members of the scientific committee were invited to
discuss deletion from the checklist for items with less
than 50 % of agreement on relevance in the broad
rating step, and to consider rephrasing for items with
less than 50 % of agreement on readability. Comments
of the broad rating panel were also used to complete
the explanatory document. A final version of the
reporting guideline, comprising a checklist and an ex-
planatory document, was approved by the scientific
committee through online discussions.
Results
Discussion and refinement step
Among the 16 experts invited to form the scientific
committee, 11 responded (PBo, PBu, JD, TD, RF, AF, MK,
ML, DM, KM, EvE). Twenty of the 25 items were rated as
relevant for the reporting of studies on TTD by seven or
more experts (including 13 rated relevant by nine or more
experts), three items were deleted because less than five
experts rated them as relevant (Additional file 2), and 14
items were merged into six new items; other six generic
items and a template for a flowchart (Fig. 2) were added.
Nineteen items were rated readable by seven or more ex-
perts, with several comments suggesting rephrasing, and
all items were partially or completely rephrased. After an
online general discussion and approval by the scientific
committee, we obtained consensus on a revised checklist
consisting of 19 items.
Broad rating step
Among 98 authors of 45 systematic reviews on TTD
who were invited to participate, 29 (30 %) answered
at least one question and 24 (24 %) rated all the 19 items.
The topics of the systematic reviews written (or co-
written) by the 98 authors were similar to those of
the 29 responding authors (Additional file 3). Seventeen
(59 %) of the 29 responding authors had already published
a primary study on TTD, in addition to one or more
systematic reviews.
All items were rated as relevant by at least 21 authors
(88 % of the 24 responding authors). All items were
rated as readable by at least 17 (71 %) of the 24 respond-
ing authors who rated all the items, while 19 items were
rated as readable by at least 19 (80 % of the 24 respond-
ing authors) (Additional file 4). Among the 22 authors
who answered the question, 19 (86 %) stated that they
would potentially use the reporting guideline in the fu-
ture. Among these, 10 had already conducted one or
more primary studies on TTD. Three authors of system-
atic reviews commented that the Aarhus statement
would be more appropriate to their fields of research.
Final version of the checklist
Given that the 19 proposed items were deemed relevant
and readable by a majority of respondents of the broad
rating panel, we decided to submit an unchanged
checklist to the scientific committee. The explanatory
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document was completed and also submitted to the
scientific committee.
Both documents were endorsed by the scientific com-
mittee (Table 1 and Additional file 5). Six items of the
checklist focus on the reporting of how participants
were selected (see items 3–6 and 14–15 in Table 1) with
a suggested flowchart to report each step of the partici-
pant selection process, from the source population
(population with signs and symptoms that are usually
used by health professionals to trigger the diagnostic
procedure) to participants with data analyzed. Six items
concern the reporting of the definition and measure-
ment of TTD (items 7–10 and 16–17), and three items
focus on the reporting of analyses of the association be-
tween TTD and participant characteristics and health
outcomes (items 10, 12, and 17). Items 1–5, 7–9, 11,
13–16, and 18 are mandatory for all types of studies on
TTD and other items are optional depending on the
studied condition (item 6) or the aim of the study (items
10, 12, 17, and 19).
Discussion
We propose a new guideline (REST) for TTD studies to
help authors, reviewers, and editors improve the reporting
of these studies. The 19-item checklist (Table 1), along
with the explanatory document (Additional file 5), have
been approved by an international panel of experts in the
field of research methodology, epidemiology and TTD
studies, journal editors, and also by 71 to 88 % of respond-
ing authors of systematic reviews on TTD published be-
fore 2014. Our reporting guideline highlights key aspects
that are specific to studies on TTD: how participants were
selected, the definition and measurement of TTD, and the
analyses of the association between TTD and participant
characteristics and health outcomes. The flowchart sug-
gested to illustrate each step of the participant selection
Fig. 2 Template flowchart for studies on time to diagnosis (see item 14 on Table 1)
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process could help raise awareness among authors, re-
viewers, and editors of threats to generalizability of study
findings and conclusions. Indeed, the differences between
the source and the analyzed populations were found to be
an important source of concern in the abovementioned
systematic review of studies on TTD [1].
A complete and accurate report of the definition and
measurement of TTD is also of importance to enable
readers to critically evaluate the risk that estimates of
TTD may be biased by a subjective definition of time
points (i.e., time of first symptoms and time of diagno-
sis). Whether the assessment of these time points was




1 Identify the article as a study on time to diagnosis
Introduction
2aa Explain the scientific background and rationale for the study
2ba State specific objective(s)
Methods
3a Describe the setting, location(s), and relevant dates, including periods of recruitment
4 State eligibility criteria of participants (i.e., inclusion and exclusion criteria, especially diagnostic criteria)
5 Describe the source population (i.e., the population with signs and symptoms that usually trigger healthcare
professionals to initiate the diagnostic procedures) and how the participants were identified within it
6b State how known subgroups of participants with an inherent individual risk of short or long time to
diagnosis were handled (e.g., by subgroup analysis, exclusion)
7 Define time points (e.g., time of first signs and symptoms, time of diagnosis) and time intervalsb
(e.g., patient or physician intervals)
8a State the methods used to collect study data (e.g., extraction from medical records, participant interview
or questionnaires, analysis of an already existing database, other)
9 Describe how time points were assessed (e.g., number of assessors, their qualifications)
10ab If the study aimed to evaluate associations between participant characteristics and time to diagnosis,
state whether assessors of time to diagnosis were blinded to these characteristics
10bb If the study aimed to evaluate associations between time to diagnosis and participant health outcomes
(e.g., survival), state whether assessors of time to diagnosis were blinded to these outcomes
11 Describe the statistical methods used, including whether time to diagnosis was analyzed as a continuous
or categorized variable (e.g., delayed versus not delayed)
12b If the study aimed to evaluate associations between time to diagnosis and other factors (e.g., participant
characteristics or health outcomes), describe which confounders were considered and how they were
chosen, measured and analyzed
13a Give a rationale for the sample size
Results
14 Report the number of individuals at each step of the selection process between the source population
and participants with data analyzed and provide a flowchart (see example); give reasons for
non-participation at each stage
15a Report demographic and clinical characteristics of participants
16 Report the distribution of time to diagnosis
17b If associations between time to diagnosis and other factors (e.g., participant characteristics or health outcomes)
were described, report measures of association and their precision (e.g., confidence intervals)
Discussion
18a Summarize key results with reference to study objectives and discuss their potential clinical implications
19a Discuss sources of potential bias, including bias due to the selection of participants from the source population
(e.g., undiagnosed cases) and to the assessment of time points
19bb If association between time to diagnosis and survival was studied, discuss possible lead-time bias
aItems common with other reporting guidelines (CONSORT, STARD, STROBE) in their meaning
bOptional items depending on the studied condition or the study objectives
cAuthors should precisely state the page number on which the item is reported, or NA if not applicable
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blinded to potential determinants and health outcomes
is also critical.
Recommendations for the development of reporting
guidelines suggest that key information concerning risk
of bias should be included in all new or revised report-
ing guidelines. Ideally, identification of key information
should rely on the empirical demonstration that it is
related to risk of bias or threats to generalizability.
For example, such demonstration has helped illustrate
the influence of randomization methods on the esti-
mation of a treatment effect in randomized controlled
trials, supporting their emphasis in CONSORT [15].
In the present reporting guideline, judgment on each
item’s potential influence on results was not based on
an empirical demonstration, but on expert consensus.
At present, an empirical demonstration is not possible,
owing to the limited number of TTD studies investigating
the same disease.
The methods used to develop this checklist are almost
all in accordance with recommendations from the
EQUATOR network, with a preparatory literature ana-
lysis [1] and vigilance about theoretical risk of bias and
threats to generalizability [4]. For feasibility reasons, the
discussion and refinement step was conducted by on-
line discussions rather than a face-to-face meeting as
recommended by the EQUATOR network. This on-line
discussion could have limited the debate but it also
allowed an independent expression of experts’ opinions
without risk of authoritarian arguments. The response
rate in the broad rating step was low (30 %), but the
topics covered by the systematic review published by
responding authors were representative of those of the
invited authors. In the broad rating step, participants
were all authors of systematic reviews; their methodo-
logical background is therefore likely to have been
stronger than that of most potential users of our
reporting guideline. An explanatory document was pro-
duced to help less initiated authors to properly use the
reporting guideline.
Conclusion
By estimating the magnitude of TTD for a disease,
evaluating its potential consequences on prognosis and
understanding its determinants, reports of studies on
TTD may be used by clinicians and decision makers to
plan corrective actions and identify inequities in access
to healthcare. Critical appraisal is a key step before using
results of clinical research for decisions in healthcare
and policy. Incomplete and inaccurate reporting may
prevent adequate critical appraisal of a study and lead to
non-contributory scientific research [16]. Our reporting
guideline provides authors, reviewers, and editors, as
well as users of studies on TTD, with a tool that pro-
motes complete and accurate reporting of studies.
Additional files
Additional file 1: The 35-item checklist previously used to evaluate the
completeness of reporting of studies on time to diagnosis. (DOCX 18 kb)
Additional file 2: The 25-item checklist submitted to the scientific
committee with a synthesis of the discussion and refinement steps
(numbers of experts). Items in red were deleted after this first round.
(DOCX 21 kb)
Additional file 3: Distribution of the topics of the systematic reviews
written (or co-written) by the invited and the responding authors in the
broad rating step. (DOCX 17 kb)
Additional file 4: Synthesis of ratings of the broad rating panel
(numbers of experts). (DOCX 20 kb)
Additional file 5: Explanatory document accompanying the checklist.
(DOCX 209 kb)
Availability of data and materials
All data supporting the results presented are included within the article or its
supporting information.
Authors’ contributions
EL and MC had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the data
analysis. EL, JFC, PR, and MC designed the study. PR and MC supervised the
study. All authors contributed to analysis and interpretation of the data. EL,
JFC, and MC drafted the manuscript. All authors critically revised the
manuscript for important intellectual content. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This work does not involve any humans, human data, or animals.
Author details
1Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epopé),
Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris
Descartes University, INSERM U1153, Maternité de Port-Royal, 53 Avenue de
l’Observatoire, 75014 Paris, France. 2CHU de Nantes, Hôpital Mère-Enfant,
Services de Pédiatrie Générale et d’Urgences Pédiatriques, Nantes, France.
3Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades; AP-HP;
Université Paris Descartes, Paris, France. 4Department of Clinical
Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands. 5School of Public
Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
6Institute of Applied Health Research, University of Birmingham, Birmingham,
UK. 7Biomedical Informatics, Clinical and Translational Science Institute,
University of Rochester, Rochester, NY, USA. 8Division of Epidemiology and
Biostatistics, School of Medicine, University of Leeds, Leeds LS2 9JT, UK.
9Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori,
Milano, Italy. 10Departments of Pediatrics and of Epidemiology, Biostatistics
and Occupational Health, McGill University Faculty of Medicine, Montreal,
Quebec, Canada. 11Centre for Practice Changing Research, Ottawa Hospital
Research Institute, School of Epidemiology, Public Health and Preventive
Medicine, University of Ottawa, Ottawa, ON, Canada. 12Julius Center for
Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.
13Cochrane Switzerland, Institute of Social and Preventive Medicine,
Lausanne University Hospital, Lausanne, Switzerland. 14Inserm UMR 1153,
METHODS Team, Center for Epidemiology and Statistics Sorbonne Paris Cité
(CRESS), Paris Descartes University, AP-HP, Paris, France.
Received: 12 July 2016 Accepted: 8 September 2016
Launay et al. BMC Medicine  (2016) 14:146 Page 6 of 7
References
1. Launay E, Morfouace M, Deneux-Tharaux C, Gras le-Guen C, Ravaud P,
Chalumeau M. Quality of reporting of studies evaluating time to diagnosis:
a systematic review in paediatrics. Arch Dis Child. 2014;99:244–50.
doi:10.1136/archdischild-2013-304778.
2. Brasme J-F, Morfouace M, Grill J, Martinot A, Amalberti R, Bons-Letouzey C,
et al. Delays in diagnosis of paediatric cancers: a systematic review and
comparison with expert testimony in lawsuits. Lancet Oncol. 2012;13:e445–59.
doi:10.1016/S1470-2045(12)70361-3.
3. Scherdel P, Dunkel L, van Dommelen P, Goulet O, Salaün J-F, Brauner R, et al.
Growth monitoring as an early detection tool: a systematic review. Lancet
Diabetes Endocrinol. 2016;4(5):447–56. doi:10.1016/S2213-8587(15)00392-7.
4. Launay E, Cohen JF, Morfouace M, Gras-Le Guen C, Ravaud P, Chalumeau M.
Inadequate critical appraisal of studies in systematic reviews of time to diagnosis.
J Clin Epidemiol. 2016. Ahead of print. doi:10.1016/j.jclinepi.2016.03.013.
5. International Confederation of Childhood Cancer Parent Organizations.
2013. http://cms.onlinebase.nl/userfiles/c1icccpo/file/WHO_leaflet.pdf.
Accessed 20 Sept 2016.
6. National Library of Medicine. Early diagnosis. Medical Subject Headings.
National Library of Medicine, Bethesda, USA. http://www.ncbi.nlm.nih.gov/
mesh/?term=early+diagnosis. Accessed 28 Jun 2015.
7. Brasme J-F, Chalumeau M, Oberlin O, Valteau-Couanet D, Gaspar N. Time to
diagnosis of Ewing tumors in children and adolescents is not associated
with metastasis or survival: a prospective multicenter study of 436 patients.
J Clin Oncol. 2014;32:1935–40. doi:10.1200/JCO.2013.53.8058.
8. Brasme J-F, Grill J, Doz F, Lacour B, Valteau-Couanet D, Gaillard S, et al. Long
time to diagnosis of medulloblastoma in children is not associated with
decreased survival or with worse neurological outcome. PLoS One.
2012;7:e33415. doi:10.1371/journal.pone.0033415.
9. Moynihan R, Henry D, Moons KGM. Using evidence to combat overdiagnosis
and overtreatment: evaluating treatments, tests, and disease definitions
in the time of too much. PLoS Med. 2014;11:e1001655. doi:10.1371/
journal.pmed.1001655.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
JP, et al. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. J Clin Epidemiol. 2008;61:344–9. doi:10.1016/j.jclinepi.2007.11.008.
11. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al.
STARD 2015: an updated list of essential items for reporting diagnostic
accuracy studies. BMJ. 2015;351:h5527.
12. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. The Aarhus
statement: improving design and reporting of studies on early cancer
diagnosis. Br J Cancer. 2012;106:1262–7. doi:10.1038/bjc.2012.68.
13. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of
health research reporting guidelines. PLoS Med. 2010;7:e1000217.
doi:10.1371/journal.pmed.1000217.
14. Development of a reporting guideline for reporting studies on time to
diagnosis. http://www.equator-network.org/wp-content/uploads/2009/02/
Reporting-studies-on-time-to-diagnosis-summary.pdf. Accessed 30 Aug 2015.
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias.
Dimensions of methodological quality associated with estimates of
treatment effects in controlled trials. JAMA. 1995;273:408–12.
16. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al.
Reducing waste from incomplete or unusable reports of biomedical
research. Lancet. 2014;383:267–76. doi:10.1016/S0140-6736(13)62228-X.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Launay et al. BMC Medicine  (2016) 14:146 Page 7 of 7
